Tag: Biomedical Advanced Research and Development Authority
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.
Featured Article
Australian Manufacturing Week 2026 enters final run-up to Brisbane debut
Australia’s manufacturing sector continues to play a critical role in the national economy, underpinned by ongoing investment in advanced technologies, automation, and high-value production.
